Sort
17,828 grants matching “crispr”
The Role of Limch1 Alternative Splicing in Skeletal Muscle Function
$47,093Matthew Penna · Baylor College Of Medicine · F31 · FY2022 · AR
Investigating GWAS-nominated risk genes associated with Parkinson's disease using a CRISPR-based toolkit
$47,079Atehsa Asal Sahagun · University Of California Berkeley · F31 · FY2025 · NS
The roles of UV, neoantigens, and epitope spreading in vitiligo and melanoma
$47,012Jennifer A Lo · Harvard Medical School · F30 · FY2015 · ES
Defining the molecular and cellular basis of morphological diversity in Drosophila
$46,972Benjamin James Vincent · University Of Pittsburgh At Pittsburgh · F32 · FY2021 · GM
Balancing epithelial cell resistance and resilience to respiratory viral infections
$46,967Jose Manuel Ordovas-Montanes · Boston Children'S Hospital · R01 · FY2023 · HL
Programmable RNA-targeting CRISPR-Cas tools to study RNA biology
$46,902Mitchell O'Connell · University Of Rochester · R35 · FY2020 · GM
Membrane Ubiquitin Ligase-Driven Immune Evasion in HPV+ Head and Neck Cancer
$46,848Lexi Vu · Henry Ford Health + Michigan State University Health Sciences · F31 · FY2024 · DE
Mechanisms of Primary Cilium Assembly and Disassembly
$46,813David King Breslow · Yale University · R35 · FY2024 · GM
The Interplay Between PD-1 Blockade and T cell Development in the Context of Thymic Regeneration in Prostate Cancer
$46,752Breanna Caruso · Oregon Health & Science University · F31 · FY2022 · CA
Determining cis- and trans- regulatory mechanisms of epigenetic bivalency
$46,752Kira Marshall · Yale University · F31 · FY2022 · HD
Identifying the Distinct Intracellular Pathways That Mediate Dopamine-Driven Behaviors
$46,752Caroline Rauffenbart · Columbia University Health Sciences · F31 · FY2022 · DA
The role of APOE and Bone Morphogenic protein 4 (BMP4) in early cellular pathophysiology of Alzheimer's Disease
$46,752Anne Kathryn Linden · Northwestern University At Chicago · F31 · FY2022 · AG
Investigating and targeting metabolic vulnerabilities of MYC-driven small cell lung cancer
$46,752Abbie Shaye Ireland · Duke University · F31 · FY2022 · CA
Anti-CRISPR-mediated Acylation and Bioreversible Esterification for Precision Genome Editing
$46,752Axel O Vera · Massachusetts Institute Of Technology · F31 · FY2022 · GM
Mechanisms and functions of CRISPR-Casautoregulation in bacterial immunity and pathogenesis
$46,752Rachael Workman Sparklin · Johns Hopkins University · F31 · FY2022 · GM
Establishing the cohort of early active zone proteins and their role in synaptic strength and maturation at the Drosophila neuromuscular junction.
$46,752Ellen Guss · Massachusetts Institute Of Technology · F31 · FY2022 · NS
Elucidating the Role of Noradrenergic Circuitry in Aversive Contextual Processing
$46,752Eric Zhang · University Of Washington · F31 · FY2022 · MH
Function of Musashi-2 Methylation in Normal and Malignant Hematopoiesis
$46,752Chiara Maria Evans · Weill Medical Coll Of Cornell Univ · F31 · FY2022 · CA
Investigating the Role of NKX2-1 in Early Human Lung Development Using an Induced Pluripotent Stem Cell (iPSC) Model
$46,752Taylor Matte · Boston University Medical Campus · F31 · FY2022 · HL
Identifying Mechanisms of Aurora Kinase A in Centrosome Clustering Using Chemical Genetics
$46,752Gina M Tomarchio · Weill Medical Coll Of Cornell Univ · F31 · FY2022 · CA
Retinal Ganglion Cell Subtype Specification in Human Retinal Organoids
$46,752Brian Guy · Johns Hopkins University · F31 · FY2022 · EY
Mechanisms and consequences of 3'UTR isoform diversity in erythropoiesis
$46,752Matthew Robert Gazzara · University Of Pennsylvania · F31 · FY2022 · HL
Mechanism of Transformation in T-Cell Lymphomas: Identification of Therapeutic Targets
$46,752Bobby Ben Shih · Columbia University Health Sciences · F31 · FY2022 · CA
Molecular Mechanisms of FUNDC1-Mediated Mitophagy
$46,752Jose M Delgado · Dartmouth College · F31 · FY2022 · GM
Spatiotemporal regulation of thyroid hormone signaling in cone subtype specification in human retinal organoids
$46,752Christina Lynne McNerney · Johns Hopkins University · F31 · FY2022 · EY